RxDoctor Payments Data

Lisa Webster, APRN

Family · Centreville, MDNPI 1467142356

Payments from drug & device makers

$870in general payments, 2019–2025

Across 38 payments — averaging $22.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$181
  • Dexcom, Inc.$149
  • Merck$119
  • AstraZeneca$111
  • Exact Sciences$71
  • GSK$51
  • plus $188 from 7 others

What the payments were for

  • Food & beverage$870100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$870 in reported general payments places this provider in the 65th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$63,156
Medicare patients
204
Services billed
739

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide66$86,573
JardianceEmpagliflozin55$37,784
OzempicSemaglutide21$24,780
EliquisApixaban22$19,836
FarxigaDapagliflozin Propanediol16$16,385
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$14,205
XareltoRivaroxaban16$11,750
MyrbetriqMirabegron15$10,234
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$6,595
Gabapentin125$2,546
Ezetimibe50$2,394
Atorvastatin Calcium141$1,884
Albuterol Sulfate HfaAlbuterol Sulfate55$1,828
Rosuvastatin Calcium78$1,462
Amlodipine Besylate137$1,435

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$30$86,57366 claims
Novo NordiskOzempic$24$24,78021 claims
GSKAnoro Ellipta, Trelegy Ellipta$51$20,80034 claims
PfizerEliquis$39$19,83622 claims
AstraZenecaFarxiga$111$16,38516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,843 family providers in Maryland.

Other family in Centreville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →